uniQure (NASDAQ:QURE) Upgraded at StockNews.com

uniQure (NASDAQ:QURE) was upgraded by analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday.

Several other equities analysts have also issued reports on QURE. Royal Bank of Canada cut their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a research report on Tuesday. Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a report on Tuesday. Finally, The Goldman Sachs Group lowered their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

uniQure Price Performance

NASDAQ QURE opened at $15.30 on Wednesday. The firm’s 50 day moving average price is $6.42 and its 200-day moving average price is $6.15. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. uniQure has a 52-week low of $3.73 and a 52-week high of $17.39.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Sell-side analysts forecast that uniQure will post -3.74 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares in the last quarter. SG Americas Securities LLC purchased a new position in uniQure in the 2nd quarter valued at about $79,000. Clear Harbor Asset Management LLC boosted its holdings in uniQure by 35.2% in the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after buying an additional 12,500 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in uniQure during the 2nd quarter worth approximately $815,000. Finally, Privium Fund Management B.V. raised its holdings in shares of uniQure by 10.6% during the second quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after acquiring an additional 61,501 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.